A recent study confirms the innovative Vidac Pharma strategy in cancer treatment. Vidac Pharma Holding PLC continues to benefit from support for its approach to mitochondrial transplantation aimed at improving the response of tumor cells to chemotherapy. This innovation is recognized to reduce the undesirable effects of cancer treatments.
The study highlights the role of mitochondria in tumor biology, suggesting new possibilities of combined therapies. Vidac Pharma’s method aims to interrupt the Warburg effect, a unique cancer metabolic process, blocking the binding of hexokinase 2 in mitochondria. Clinical studies show that this improves the immune response within tumors.
Using a model to update cash flows with several stages, vidac development drugs for actinic keratosis and T -cell skin lymphoma are valued individually. The company maintains a price target of EUR 4.30, with a purchase recommendation.
R. H.
